NCT06747858Phase 2Recruiting

Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

Study sponsor: Arcturus Therapeutics, Inc.

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-06Estimated
Enrollment · participants33Estimated
Source updated2026-05-08Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Planned enrollment increased by 21 participants

Before: 12 participants (planned). After: 33 participants (planned).

Primary completion date changed

Before: Dec 2025. After: Jun 2027.

Check registry source